Introduction

The immune response constitutes the primary biological defense mechanism that safeguards the body from diverse threats, including microorganisms such as bacteria, viruses, fungi, and parasites, as well as complex foreign substances. This multifaceted system comprises 2 principal components, innate and adaptive, each performing distinct yet complementary functions. Innate immunity provides an immediate, nonspecific defense against invading pathogens or cellular damage, whereas adaptive immunity exhibits specificity and immunologic memory, enabling a more potent response upon subsequent exposure.

Innate immunity depends initially on physical barriers such as the skin, mucous membranes, and protective secretions, including saliva and tears, which restrict pathogen entry. Chemical mediators such as lysozyme and defensins disrupt microbial membranes, while the complement cascade promotes opsonization and direct lysis of target cells. Cellular components, including neutrophils, basophils, eosinophils, monocytes or macrophages, dendritic cells, natural killer cells, mast cells, and epithelial and endothelial cells, continuously survey tissues, detect molecular danger signals through pattern recognition receptors, and activate downstream effector mechanisms.

Adaptive immunity involves the activation of lymphocytes—B cells and T cells—that exhibit highly specific antigen recognition mediated by somatically rearranged receptors. B lymphocytes produce antigen-specific immunoglobulins that neutralize pathogens or facilitate their clearance through opsonization and complement activation. CD4+ helper T lymphocytes coordinate immune activity by secreting cytokines that modulate B-cell differentiation and enhance cytotoxic CD8+ T lymphocyte responses, which directly eliminate infected or neoplastic cells. This arm of immunity is characterized by clonal expansion and the establishment of immunologic memory, fundamental mechanisms underlying vaccine efficacy and durable protection.

Inflammation comprises a critical component of innate immunity, providing a rapid response to epithelial disruption by recruiting leukocytes and releasing cytokines that confine infection and initiate adaptive immune activation. Regulation of immune specificity is essential. Disruption of self-tolerance mechanisms can precipitate autoimmune pathology, whereas insufficient immune activity increases susceptibility to infection and malignancy.

Issues of Concern

Immunodeficiencies

Immunodeficiencies arise from genetic abnormalities or acquired conditions that compromise the capacity to generate effective immune responses, thereby predisposing affected individuals to recurrent infections and malignancies. Primary (congenital) immunodeficiencies include X-linked agammaglobulinemia, characterized by an absence of mature B lymphocytes and defective antibody production; severe combined immunodeficiency (SCID), marked by profound impairment of both T- and B-lymphocyte function; and chronic granulomatous disease, resulting from defective phagocytic generation of reactive oxygen species (ROS) essential for microbial killing.

Therapeutic strategies depend on the underlying defect but generally focus on infection prevention and immune restoration. Intravenous immunoglobulin therapy provides passive immunity by supplying exogenous antibodies. Hematopoietic stem cell transplantation or bone marrow transplantation offers potential curative outcomes in select disorders by reconstituting immune function with donor-derived hematopoietic cells. Emerging gene therapy techniques utilizing lentiviral vectors to correct autologous hematopoietic stem cells have demonstrated efficacy in inherited immunodeficiencies such as SCID and Wiskott-Aldrich syndrome, mitigating risks associated with donor mismatch and graft-versus-host disease. Early recognition and coordinated interprofessional management are critical to improving long-term prognosis.

Autoimmune Diseases

Autoimmune diseases develop when immunologic tolerance to self-antigens fails, resulting in inappropriate immune activation directed against host tissues and organs. This dysregulation manifests as systemic disorders, exemplified by systemic lupus erythematosus (SLE), which involves multisystem inflammation and production of diverse autoantibodies, or as organ-specific diseases such as autoimmune thyroiditis and type 1 diabetes mellitus, wherein immune responses selectively target the thyroid gland and pancreatic islets, respectively.

Pathogenesis reflects a multifactorial interaction among genetic predisposition, environmental influences, and defects in immune regulatory mechanisms. Imbalances in T-helper cell subsets, impaired function of regulatory T cells (Tregs), and aberrant activation of B lymphocytes contribute to chronic inflammation and progressive tissue injury. Management strategies focus on suppression of immune-mediated damage through immunosuppressive agents, biologic therapies targeting specific cytokines (eg, tumor necrosis factor inhibitors), and investigational cellular approaches designed to reestablish immune tolerance. Advancements in personalized medicine increasingly enable treatment individualization according to disease phenotype and patient-specific immunologic profiles.[1]

Hypersensitivity

Hypersensitivity reactions represent exaggerated or deleterious immune responses to antigens that ordinarily elicit controlled physiological reactions. These responses are classically categorized into 4 types based on underlying immunologic mechanisms.

• Type I (immediate) hypersensitivity: Mediated by immunoglobulin E (IgE) antibodies that sensitize mast cells and basophils. Upon reexposure to the allergen, cross-linking of surface-bound IgE induces the release of histamine, prostaglandins, and leukotrienes, resulting in vasodilation, bronchoconstriction, and increased vascular permeability. Clinical manifestations include allergic rhinitis, bronchial asthma, urticaria, and anaphylaxis.
• Type II (antibody-dependent cytotoxic) hypersensitivity: Directed against antigens expressed on cell membranes. Antibody binding activates the complement cascade and recruits cytotoxic effector cells, culminating in cellular destruction. Representative conditions include autoimmune hemolytic anemia, immune thrombocytopenia, and transfusion reactions.
• Type III (immune complex-mediated) hypersensitivity: Involves the formation of soluble antigen-antibody complexes that deposit in tissues, initiating complement activation and inflammatory injury. Clinical examples include serum sickness, SLE, and poststreptococcal glomerulonephritis.
• Type IV (delayed-type) hypersensitivity: Mediated by sensitized T lymphocytes, primarily CD4+ T helper type 1 cells, which release cytokines that activate macrophages and induce localized tissue damage. Contact dermatitis, tuberculin skin reaction, and granulomatous inflammation exemplify this category.

Management emphasizes avoidance of known antigens, pharmacologic symptom control using antihistamines and corticosteroids, and the application of immunomodulatory or desensitization therapies in chronic or severe cases.[2] Advances in understanding the molecular mechanisms of hypersensitivity have facilitated the development of targeted biologic agents that selectively attenuate pathogenic immune responses.

Complement Deficiencies

The complement system, a proteolytic cascade of plasma proteins, constitutes a critical component of innate immunity by facilitating opsonization, promoting inflammation, and mediating direct pathogen lysis. Deficiencies in complement components, whether congenital or acquired, increase susceptibility to recurrent infections, particularly those caused by encapsulated bacteria such as Neisseria meningitidis, and predispose to immune complex-mediated diseases due to impaired clearance of antigen-antibody complexes.

Deficiency of early classical pathway components (C1q, C2, C4) is strongly associated with lupus-like autoimmune manifestations, whereas absence of terminal pathway components (C5-C9) markedly elevates the risk of meningococcal infection. Diagnostic evaluation relies on quantitative measurement and functional assessment of complement activity. Management is largely supportive, emphasizing infection prevention through immunization and prophylactic antibiotic therapy. Ongoing research into complement regulation offers potential avenues for targeted therapeutic intervention.[3]

Transplant Rejection

Transplant rejection remains a major obstacle to successful organ transplantation despite substantial progress in immunosuppressive therapy. Rejection is classified into hyperacute, acute, and chronic forms based on the timing and underlying immunologic mechanisms.

Hyperacute rejection occurs within minutes to hours after transplantation and results from preexisting recipient antibodies directed against donor antigens. Antibody binding activates the complement cascade, leading to rapid vascular thrombosis and immediate graft loss. Acute rejection typically develops within weeks to months posttransplantation and involves activation of recipient T lymphocytes that recognize donor major histocompatibility complex (MHC) molecules as foreign. Concurrent antibody-mediated injury may occur, contributing to vascular inflammation and parenchymal damage characterized histologically by vasculitis and interstitial infiltrates.

Chronic rejection represents a progressive process evolving over months to years, often as a consequence of recurrent or unresolved acute rejection episodes. Persistent immune-mediated injury induces fibrosis, vascular intimal thickening, and parenchymal atrophy, culminating in gradual graft dysfunction. Clinically, this manifests as accelerated coronary artery disease in cardiac allografts or bronchiolitis obliterans in pulmonary transplants.

Prevention and management rely on immunosuppressive regimens, histocompatibility matching, and rigorous posttransplant monitoring. Emerging therapeutic strategies targeting costimulatory signaling and enhancing regulatory immune cell function offer potential to improve long-term graft survival.[4]

Cellular Level

The immune cellular landscape comprises a diverse array of specialized cells that coordinate host defense and immune regulation. Dysregulation of these cellular populations contributes to the pathogenesis of autoimmune disease, immunodeficiency, infection susceptibility, and malignancy.

Phagocytic cells, including monocytes and macrophages, continuously patrol tissues and the systemic circulation, recognizing invading pathogens through pattern recognition receptors such as toll-like receptors (TLRs). These cells internalize and destroy microorganisms via phagocytosis and function as antigen-presenting cells (APCs), thereby linking innate and adaptive immune responses.

Neutrophils act as the primary responders to infection or tissue injury, rapidly recruited in large numbers to sites of inflammation. During pregnancy, neutrophil counts progressively increase from early gestation, with basal production of ROS remaining elevated at rest but attenuated upon activation to preserve antimicrobial defense while minimizing fetal injury. Eosinophils and basophils contribute to antiparasitic immunity and hypersensitivity reactions, exhibiting modulation of degranulation activity during gestation.

Natural killer cells play a pivotal role in identifying and eliminating stressed, infected, or neoplastic cells through recognition of absent or altered MHC-I molecules. These lymphocytes exert cytotoxic effects independent of prior antigen sensitization. Circulating natural killer cell populations decline during pregnancy, although expression of activation markers such as TIM-3 and CD69 increases, reflecting a state of controlled activation that promotes maternal-fetal immune tolerance while maintaining surveillance capacity.

T lymphocytes constitute key effectors of adaptive immunity and are categorized into several functionally distinct subsets. CD4+ helper T cells orchestrate immune activity through cytokine secretion, thereby regulating both cellular and humoral responses. CD8+ cytotoxic T lymphocytes (CTLs) directly eliminate virus-infected or neoplastic cells, while Tregs suppress autoreactive lymphocytes to maintain immune homeostasis. During pregnancy, expansion and functional modulation of Tregs are critical in preventing maternal immune recognition of the fetus as foreign. Distinct T-cell subsets display dynamic cytokine expression profiles across gestational stages, influenced by hormonal fluctuations involving estrogens and progesterone.

B lymphocytes serve as the source of immunoglobulins, residing within secondary lymphoid organs and circulating in peripheral blood. Upon antigen encounter, B cells differentiate into plasma cells that secrete antigen-specific antibodies. Peripheral B-cell numbers decline during late pregnancy, a phenomenon attributed to hormonal suppression and tissue redistribution, particularly toward the placenta. Regulatory B cells producing interleukin 10 (IL-10) increase in early gestation, contributing to maternal-fetal tolerance by limiting excessive inflammatory responses.

TLRs, expressed across multiple immune cell types, recognize conserved pathogen-associated molecular patterns and initiate signaling cascades that drive inflammatory and antiviral defenses while promoting adaptive immune activation. The structural diversity and subcellular compartmentalization of TLRs enhance the immune system’s capacity to discriminate among microbial constituents and endogenous damage-associated signals, ensuring a balanced yet effective immune response.

Development

Hematopoiesis originates embryonically from mesoderm-derived hemangioblasts, which generate definitive hematopoietic stem cells within the aorta-gonad-mesonephros region. These primitive progenitors subsequently migrate to the fetal liver, the principal hematopoietic organ during gestation, before colonizing the bone marrow in late fetal life and after birth. The bone marrow then becomes the primary and lifelong site of blood cell formation.

Pregnancy induces extensive reprogramming of maternal immunity through a dynamic “immune clock,” characterized by alternating proinflammatory and anti-inflammatory phases aligned with key stages of gestation. The initial proinflammatory environment promotes embryo implantation and placental development. This phase transitions into an anti-inflammatory state that sustains fetal growth and prevents excessive maternal immune activation against fetal antigens. Near term, a return to a proinflammatory state facilitates the onset of labor and delivery.

This temporally regulated immunologic adaptation results from coordinated interactions among immune cells, cytokines, endocrine mediators, and placental-derived factors. These mechanisms collectively maintain maternal immune tolerance while providing effective protection for the developing fetus throughout gestation.

Organ Systems Involved

The architecture of the immune system is organized around primary and secondary lymphoid organs that coordinate immune cell development and activation. These organs comprise the thymus and bone marrow, along with peripheral lymphoid tissues such as the spleen, lymph nodes, and mucosal immune aggregates.

The thymus functions as the site of T-lymphocyte maturation and selection, eliminating self-reactive clones, while the bone marrow generates B lymphocytes and all hematopoietic lineages, maintaining continuous immune cell renewal. Secondary lymphoid organs, including the spleen, lymph nodes, tonsils, and mucosa-associated lymphoid tissue (MALT), serve as major sites for antigen recognition, lymphocyte activation, and clonal expansion. The liver contributes to immune regulation through the production of acute-phase proteins and the activity of resident macrophages (Kupffer cells), which maintain systemic immune surveillance. Excessive cytokine release from these sites may precipitate systemic inflammatory responses such as endotoxin shock.

The structural integrity and coordinated function of these organs are essential for effective immune defense and the prevention of aberrant or pathological inflammation. Factors such as immunosenescence, metabolic imbalance, and environmental stressors progressively erode lymphoid tissue function, predisposing to immune dysregulation and disease.

Function

The immune system operates as an integrated defense network that safeguards the host against a wide range of pathogens. Specific and coordinated responses are generated, adapted to the molecular and structural characteristics of each invader.

Immune Response to Bacteria

Following bacterial invasion, the immune system mounts both humoral and cellular defenses to limit infection. Neutralizing antibodies bind bacterial toxins, preventing host tissue injury, while opsonizing antibodies coat bacterial surfaces to promote phagocytic uptake and destruction, particularly effective against extracellular bacteria. The complement system plays a central role in defense against gram-negative organisms by recognizing lipid A components, generating membrane attack complexes that lyse bacterial membranes, and recruiting inflammatory cells through complement-derived peptides.

Phagocytes, including neutrophils and macrophages, migrate to infection sites via chemotaxis, recognize opsonized bacteria, internalize them within phagosomes, and mediate killing through oxidative bursts and lysosomal enzymes. In infections involving intracellular bacteria, CD8+ CTLs recognize infected cells presenting bacterial peptides on MHC-I molecules and induce apoptosis, thereby restricting bacterial replication.

Immune Response to Fungi

Innate immunity constitutes the first line of defense against fungal pathogens through antimicrobial peptides such as defensins and the activity of phagocytes. Adaptive immunity centers on CD4+ T-helper cells, which orchestrate antifungal responses. Dendritic cells phagocytose fungal elements and secrete interleukin 12, promoting interferon γ production by T cells. Interferon γ subsequently activates macrophages, augmenting their fungicidal capacity and facilitating pathogen clearance.

Immune Response to Viruses

Early viral defense relies on the induction of type I interferons, which establish an antiviral state in surrounding cells, and the activation of natural killer cells that identify and eliminate infected cells, often through recognition of altered MHC-I expression. Phagocytes contribute by clearing viral particles and releasing cytokines that amplify antiviral immunity.

Adaptive immunity generates virus-specific antibodies that neutralize extracellular virions and mark infected cells for clearance. The cellular arm involves CD8+ CTLs that recognize viral peptides presented on MHC-I molecules and induce apoptosis of infected cells. CD4+ helper T cells support these processes by enhancing CTL activity and promoting B-cell differentiation and antibody production. Viral evasion strategies include antigenic variation, interference with interferon signaling, secretion of soluble decoy receptors, and downregulation of MHC expression. Certain viruses, such as HIV and Epstein-Barr virus, persist within immune cells, leading to chronic infection and immune dysregulation.

Immune Response to Parasites

Parasitic infections elicit complex and stage-dependent innate and adaptive immune responses. Both CD4+ and CD8+ T lymphocytes contribute to parasite control. Macrophages, eosinophils, neutrophils, and platelets release ROS and reactive nitrogen species to mediate the destruction of protozoa and helminths. T helper type 2-polarized responses stimulate IgE production and eosinophil activation, mechanisms that are particularly effective in the expulsion of intestinal helminths. Inflammatory mediators further recruit immune effectors to infection sites, coordinating tissue repair and pathogen clearance.

Innate Immunity

Innate immunity constitutes the body’s first nonspecific line of defense, integrating physical, chemical, cellular, and soluble mechanisms to restrict pathogen invasion. Physical and chemical barriers, including the skin, mucosal linings, saliva, tears, and gastric acid, mechanically and chemically prevent microbial entry. Cellular defenses involve phagocytes that engulf pathogens, natural killer cells that induce apoptosis in altered host cells, and mast cells and basophils that release inflammatory mediators to enhance vascular permeability and recruit additional immune effectors. Soluble mediators such as cytokines coordinate immune responses, while complement proteins facilitate pathogen lysis and opsonization, and acute-phase reactants like C-reactive protein amplify inflammation.

Adaptive Immunity

Adaptive immunity generates highly specific and memory-based responses against distinct antigens. B lymphocytes produce antigen-specific antibodies that neutralize pathogens or tag them for phagocytic clearance. T lymphocytes include CD4+ helper T cells that secrete cytokines to coordinate immune effectors and CD8+ CTLs that eliminate infected or malignant cells. APCs activate T lymphocytes through MHC-I and MHC-II pathways, initiating targeted immune responses. Clonal selection and expansion amplify antigen-specific lymphocytes, while immunological memory enables rapid, robust recall responses—the fundamental principle underlying vaccination.

Immune Response Pathways and Regulation

The immune response operates through coordinated pathways that balance activation and regulation. The inflammatory response is characterized by redness, swelling, heat, and pain, driven by vasodilation, increased vascular permeability, and chemokine-mediated leukocyte recruitment. The humoral pathway centers on antibody production by plasma B cells following T lymphocyte assistance, while the cell-mediated pathway relies on CD8+ CTLs recognizing and eliminating infected or aberrant cells. Immune activation is controlled by Tregs that suppress excessive responses, anti-inflammatory cytokines such as IL-10 and transforming growth factor β, and checkpoint molecules including CTL-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), which serve as key therapeutic targets.

Pathogen Evasion

Pathogens have evolved diverse evasion mechanisms to circumvent immune defenses. Antigenic variation allows alteration of surface proteins to escape immune recognition. Certain viruses, such as cytomegalovirus, inhibit antigen presentation, while intracellular pathogens like Mycobacterium tuberculosis resist phagocytic destruction, enabling persistent infection despite active immune surveillance.

Mechanism

The immune system orchestrates a coordinated network of mechanisms to identify and eliminate pathogens. The interplay among these pathways maximizes pathogen clearance efficiency and ensures immunologic memory essential for protection against reinfection.

Professional phagocytes internalize microbes into phagosomes that fuse with lysosomes containing degradative enzymes and ROS, ensuring microbial destruction. Cytokines facilitate intercellular communication, regulating immune cell recruitment, activation, and differentiation through receptor-mediated signaling. The complement cascade amplifies immune activity via sequential enzymatic reactions that generate opsonins, anaphylatoxins, and membrane attack complexes capable of lysing pathogens. Type I interferons induce antiviral gene expression in infected and neighboring cells, restricting viral replication.

Natural killer cells exert cytotoxic effects by releasing perforin and granzymes, inducing apoptosis in virus-infected or malignant cells lacking normal MHC-I expression. Antibody-dependent cell-mediated cytotoxicity (ADCC) occurs when Fc receptor-bearing killer cells recognize and destroy antibody-coated targets. Antigen presentation on MHC-I and MHC-II molecules activates CD8+ CTLs and CD4+ helper T cells, respectively, bridging innate and adaptive immunity. Clonal selection and affinity maturation enhance antigen-specific lymphocyte populations and improve antibody binding during secondary exposures.

Immune regulation is maintained by Tregs, anti-inflammatory cytokines such as IL-10 and transforming growth factor β, and checkpoint molecules, CTLA-4 and PD-1. TLRs detect conserved pathogen- and damage-associated molecular patterns, initiating signaling cascades that induce inflammatory mediators, type I interferons, and APC activation, thereby integrating innate and adaptive immune responses.[5]

Related Testing

Clinical monitoring of immune status integrates quantitative, functional, and diagnostic assessments. Serum immunoglobulin measurement determines total levels and subclasses (immunoglobulins G1 to G4), while antibody titers and neutralizing assays evaluate responses to vaccination or infection. Flow cytometric lymphocyte phenotyping identifies subsets such as CD3+, CD4+, CD8+, CD19+, and CD20+ populations. Functional assays assess lymphocyte proliferation, phagocyte oxidative burst through nitroblue tetrazolium reduction, and cellular chemotaxis.

Complement function is evaluated by quantifying C3 and C4 components and conducting activity assays, including CH50 for the classical and AH50 for the alternative pathways. Autoimmune profiles are established using antinuclear antibody testing, anti-double-stranded DNA, rheumatoid factor, and organ-specific autoantibodies. Microbiological evaluation employs culture and polymerase chain reaction techniques for pathogen detection. Coagulation studies and imaging may provide supporting information regarding systemic immune or inflammatory involvement.

Pathophysiology

Alterations in immune components contribute to a broad range of pathological conditions. Immunodeficiencies, whether genetic (eg, X-linked agammaglobulinemia, SCID, and chronic granulomatous disease) or acquired, markedly reduce host resistance to infection. Autoimmune diseases arise from loss of self-tolerance, producing systemic and organ-specific inflammation exemplified by SLE, autoimmune thyroiditis, and type 1 diabetes mellitus.

Hypersensitivity reactions reflect exaggerated immune responses that result in allergy, inflammation, and tissue injury. Complement deficiencies predispose to recurrent infections and immune complex-mediated disease, while transplant rejection involves antigen-specific T lymphocytes and antibodies that induce vascular damage and fibrosis in grafts. A comprehensive understanding of these immune dysfunctions is essential for developing targeted diagnostic and therapeutic strategies.

Clinical Significance

Effective immunity is a finely regulated equilibrium between mounting potent defenses against infections, malignancies, and alloantigens, and maintaining self-tolerance to prevent immune-mediated tissue injury. The capacity of the immune system to sustain this balance is fundamental to health maintenance throughout life and across diverse pathological conditions.[6]

Advances in Vaccines and Immunotherapies

Vaccination constitutes a highly effective approach to engage adaptive immunity, eliciting durable immunological memory without causing disease. Modern vaccine platforms employ diverse strategies to stimulate immune protection.

Live attenuated vaccines contain weakened pathogens that replicate minimally, mimicking natural infection and inducing robust cellular and humoral responses. Inactivated vaccines, composed of killed pathogens or pathogen subunits, primarily generate antibody-mediated immunity. Subunit vaccines utilize purified antigenic fragments to elicit targeted immune responses. Messenger RNA (mRNA) vaccines deliver genetic instructions encoding specific viral proteins within lipid nanoparticles, prompting host cells to synthesize antigens and activate adaptive immunity. This platform has transformed the rapid development of vaccines against emerging pathogens, exemplified by the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Biologic Therapies

Biologic therapies form a groundbreaking class of agents engineered to modulate the immune system with high specificity. Unlike conventional immunosuppressants, biologics are typically large protein molecules or monoclonal antibodies designed to target discrete cytokines, cell surface receptors, or immune checkpoints implicated in disease pathogenesis.

In oncology, biologics enhance tumor recognition and elimination by activating CTLs, natural killer cells, and macrophages or inhibiting immune checkpoints that tumors exploit to evade immune surveillance. Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have markedly improved outcomes, inducing durable remissions across multiple malignancies.

In autoimmune disorders, biologics, including anti-tumor necrosis factor agents, interleukin 6 (IL-6) receptor blockers, and anti-CD20 antibodies, selectively attenuate pathogenic inflammation while minimizing broad immunosuppression, thereby lowering infection risk and enhancing patient quality of life. Therapeutic regimens are individualized, with dosing tailored to disease severity and patient response. Advanced biologics utilize protein engineering and computational modeling to optimize efficacy, reduce immunogenicity, and refine precision immune modulation.[7] 

Checkpoint Inhibitors and Adoptive Cell Therapies

ICIs enhance the immune system’s intrinsic capacity to detect and eliminate malignant cells by blocking inhibitory pathways that suppress T-cell activation. This therapeutic approach has substantially improved outcomes in malignancies such as melanoma, non-small cell lung cancer, bladder cancer, and head and neck cancers, where immunotherapy has become a central component of standard care. (Source: U.S. Food and Drug Administration, 2025)

Adoptive cell therapies, including chimeric antigen receptor T cells and tumor-infiltrating lymphocyte therapies, entail the isolation, genetic modification, and ex vivo expansion of autologous immune cells to achieve targeted antitumor activity. Recent clinical trials in 2025 have demonstrated improved efficacy and safety profiles of next-generation chimeric antigen receptor T cell and tumor-infiltrating lymphocyte products, broadening therapeutic options and enhancing survival outcomes.

Personalized and Precision Immunology

Immunological research is progressively elucidating the determinants of individual immune variability. Biomarker-driven strategies integrating high-dimensional immune profiling, epigenetic signatures, and advanced imaging techniques are facilitating the development of personalized therapeutic regimens that maximize efficacy, minimize adverse effects, and improve prognostic accuracy. Precision immunology is especially vital in heterogeneous conditions such as cancer and autoimmune diseases, informing the design of tailored combination therapies and adaptive treatment protocols.

Broader Implications

Beyond oncology and autoimmune disorders, advances in immunotherapy and vaccination have significant implications for the management of infectious diseases, allergic conditions, transplantation outcomes, and chronic inflammatory disorders. The incorporation of immune-modulating strategies into clinical practice marks a new paradigm in which the immune system serves simultaneously as a therapeutic target and a critical mediator of health restoration.

In summary, immunological insights emerging from 2024 to 2025 underscore the central role of the immune system in modern medicine. Innovations in biologics, vaccines, ICIs, and adoptive cellular therapies are reshaping patient care, enhancing survival, and improving quality of life worldwide.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023 Feb;80:102266. [PMC free article: PMC9918670] [PubMed: 36446151]

2.

Zhong X, Zhao L. Hypersensitivity reactions to iodinated contrast media: potential mechanisms and clinical management. Front Med (Lausanne). 2025;12:1582072. [PMC free article: PMC12092453] [PubMed: 40400633]

3.

Conversano E, Vivarelli M. Advances in Complement Inhibitory Strategies for the Treatment of Glomerular Disease: A Rapidly Evolving Field. J Clin Med. 2025 Jun 13;14(12) [PMC free article: PMC12194467] [PubMed: 40565949]

4.

Böhmig GA, Naesens M, Viklicky O, Thaunat O, Diebold M, Rostaing L, Budde K. Antibody-mediated rejection-treatment standard. Nephrol Dial Transplant. 2025 Aug 01;40(8):1615-1627. [PMC free article: PMC12378628] [PubMed: 40440205]

5.

Xicluna R, Schwalie PC, Bell E, Von Tell D, Steiner G, Seeger E, Freen-van Heeren JJ, Turksma AW, Pouw RB, Schwandt T, Otteneder MB, Rispens T, Brouwer MC, Bertinetti-Lapatki C, Haegel H. Innate immune response to AAV-based gene therapy vectors: Mechanisms of complement activation and cytokine release. Mol Ther Methods Clin Dev. 2025 Sep 11;33(3):101551. [PMC free article: PMC12409308] [PubMed: 40917687]

6.

Shirafkan F, Hensel L, Rattay K. Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis. Front Immunol. 2024;15:1339714. [PMC free article: PMC10987875] [PubMed: 38571951]

7.

Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, Sethi G, Zhao P, Liu S. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025 May 07;24(1):136. [PMC free article: PMC12057291] [PubMed: 40336045]

Disclosure: Sarah Sabir declares no relevant financial relationships with ineligible companies.

Disclosure: Arif Jan declares no relevant financial relationships with ineligible companies.